StageZero to Hold Q2 2022 Operational and Financial Results Conference Call on Tuesday August 16, 2022

TORONTO, ON / ACCESSWIRE / August 12, 2022 / StageZero Life Sciences ("StageZero" or the "Company") (TSX:SZLS) today announced that it will release its second quarter operational and financial results before the markets open on Tuesday, August 16, 2022. StageZero's Chairman and CEO, James Howard-Tripp, will host a conference call and accompanying webcast at 8:30 a.m. EDT on Tuesday August 16, 2022, to review the operational results and discuss business developments to date.

Analyst and Investor Call

Event Date: Tuesday August 16, 2022
Time: 8:30 a.m. EST
Webcast Link: https://www.webcaster4.com/Webcast/Page/2082/46389

Participant Numbers:

Toll Free: 888-506-0062
International: 973-528-0011
Participant Access Code: 811487

Replay Number:
Toll Free: 877-481-4010
International: 919-882-2331
Replay Passcode: 46389

About StageZero Life Sciences, Ltd.

StageZero Life Sciences, Ltd. is a vertically integrated healthcare company dedicated to improving the early detection and management of cancer and other chronic diseases through next-generation diagnostics and unique telehealth programs that provide clinical interventions to assist patients who currently have cancer (COC Protocol) as well as help patients reduce the risk of developing late-stage disease (AVRT™).

The Company's next generation test, Aristotle®, is the first ever mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle® uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. This underlying technology has been validated in more than 9,000 patients and used by more than 100,000 patients in North America.

The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Developed by scientists and oncologists, the COC Protocol is intended for adjunctive administration alongside standard-of-care cancer therapy. It is an individualized therapeutic approach which seeks to simultaneously target multiple metabolic cancer pathways. The aim is to restrict cancer cell energy supply and use, which may make it more difficult overall for cancer cells to survive, grow and adapt to changing conditions in the body. As a result, such cells can potentially become more vulnerable to attack from cell-killing therapies such as radiotherapy and chemotherapy. Its patented COC Protocol incorporates a multifaceted approach, supported by peer-reviewed scientific studies, which highlight the potential of certain treatments to target the specific energy requirements of cancer cells, impacting their ability to grow and multiply.